Search

Recent Articles

IJMPO—A Journey of a Thousand Miles

Author : Padmaj S. Kulkarni

Coronavirus Disease 2019 Treatment—T-Cells Hold the Key in Severe Cases

Author : Kunal Das, Nitika Agrawal, Mansi Kala, Rakhee Khanduri

Why Is China Importing COVID-19 Vaccine Now?

Author : Purvish M. Parikh

The role of bacteria in oral cancer

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2010; 31(04): 126-131

DOI: DOI: 10.4103/0971-5851.76195

Abstract

Despite the widening interest in the possible association between bacteria and different stages of cancer development, our knowledge in its relation to oral cancers remains inadequate. The aim of this review article is to derive a better understanding on the role of various micro-organisms in the etiogenesis of oral cancers through all the available data on the pubmed. Different bacteria have been proposed to induce carcinogenesis either through induction of chronic inflammation or by interference, either directly or indirectly, with eukaryotic cell cycle and signaling pathways, or by metabolism of potentially carcinogenic substances like acetaldehyde causing mutagenesis. Studies have shown diversity of isolated bacterial taxa between the oral cancer tissue specimens and the control, with Exiguobacterium oxidotolerans, Prevotella melaninogenica, Staphylococcus aureus and Veillonella parvula being specific for tumorogenic tissues. Most isolates are saccharolytic and acid tolerant. Streptococcus anginosus, commonly linked with esophageal and pharyngeal cancers, is not of significance in oral cancers. Similarly, significant salivary specificity is noted for three bacteria, namely, Capnocytophaga gingivalis, P. melaninogenica, and Streptococcus mitis in oral cancer patients, making these species salivary markers for the early detection of oral cancers and thus improving the survival rate significantly. Also, such high degree of bacterial specificity in oral cancers has also provoked the designing of new treatment options for cancer prevention by way of vaccine delivery. However, for the success of these steps, a deeper exploration into this subject with a greater understanding is warranted.



Publication History

Article published online:
16 August 2021

© 2010. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

Abstract

Despite the widening interest in the possible association between bacteria and different stages of cancer development, our knowledge in its relation to oral cancers remains inadequate. The aim of this review article is to derive a better understanding on the role of various micro-organisms in the etiogenesis of oral cancers through all the available data on the pubmed. Different bacteria have been proposed to induce carcinogenesis either through induction of chronic inflammation or by interference, either directly or indirectly, with eukaryotic cell cycle and signaling pathways, or by metabolism of potentially carcinogenic substances like acetaldehyde causing mutagenesis. Studies have shown diversity of isolated bacterial taxa between the oral cancer tissue specimens and the control, with Exiguobacterium oxidotolerans, Prevotella melaninogenica, Staphylococcus aureus and Veillonella parvula being specific for tumorogenic tissues. Most isolates are saccharolytic and acid tolerant. Streptococcus anginosus, commonly linked with esophageal and pharyngeal cancers, is not of significance in oral cancers. Similarly, significant salivary specificity is noted for three bacteria, namely, Capnocytophaga gingivalis, P. melaninogenica, and Streptococcus mitis in oral cancer patients, making these species salivary markers for the early detection of oral cancers and thus improving the survival rate significantly. Also, such high degree of bacterial specificity in oral cancers has also provoked the designing of new treatment options for cancer prevention by way of vaccine delivery. However, for the success of these steps, a deeper exploration into this subject with a greater understanding is warranted.

Keywords: Bacteriacarcinogenesisoral squamous cell carcinoma

INTRODUCTION

Oral cancers rank sixth amongst the common malignancies globally,[] with a rising titer of around 40% in developing countries such as southeast Asia.[] Amongst these, 90% of all oral cancers are squamous cell carcinoma (SCC) originating from the mucosal epithelium.[]

Although etiology for 70–80% of oral cancers has been majorly linked to betel quid (tobacco) chewing, smoking and alcohol consumption,[] other factors like genetic susceptibility of the individual, external agents such as dietary factors, may exert their synergistic role in tumorogenesis. Notably, about 15% of oral cancer patients have no known risk factors, and the disease in this population may pursue a particularly aggressive course. This can be attributed to infections involving viruses [Human Papilloma Viruses (HPV) and Epstein Barr Virus (EBV)],[] fungi like Candida albicans[] and certain bacteria.[]

The role of viruses in carcinogenesis (by abrogation of p53 and pRb tumor suppressor genes and other cellular proteins involved, with subsequent alteration in the host genome function) is well documented with convincing evidences.[,]

Chronic hyperplastic candidosis, a rare oral fungal infection, is associated with the invasion of candidal hyphae into the oral epithelium and known to cause dysplastic changes leading to oral cancers.[]

Likewise, overwhelming body of study has confirmed the relationship between certain bacteria and cancers. However, there is yet no clear understanding on its mechanism and hence its role remains uncertain. This gap in knowledge makes it impossible to state the exact progression of events by which specific bacteria may cause, colonize or cure cancer.[,]

Since not much data are available to support the role of microorganisms in the etiogenesis of oral cancers, we need to further evaluate on this. With this in consideration, we conducted a retrospective systematic review on all the available data from pubmed in order to get a better understanding on the interaction of various type specific microorganisms in oral cancer, and their role in its etiogenesis, if any.

HISTORY

Several discoveries in microbiological literature since the 19th century have led its way to suggest that bacteria were implicated in all diseases, and hence, the theory of bacterial infections leading to oral cancers was born. Various epidemiological and laboratory-based studies have shown a number of bacterial species to be associated with different cancers [Table 1]. Few such propositions that gained widespread interest were the following revelations

Table 1

<!--caption a7-->

Various evidence-based cancers associated with specific bacterial etiology

Carcinomas of various regions Associated pathogen
Gastric carcinoma Helicobacter pylori
Gall bladder carcinoma Salmonella typhi
Cervical carcinoma Chlamydia trachomatis
Lung cancer Chlamydia pneumonia
Intestinal cancer Streptococcus bovis

Figure 1:Various proposed paradigms for bacterial role in carcinogenesis

  1. It has been shown that several bacteria can cause chronic infections or produce toxins that disturb the cell cycle and lead to altered cell growth.[,,]
  2. Chronic infections induce cell proliferation and DNA replication through activation of mitogen activated kinase (MAPK) pathways and cyclin D1 and increase the incidence of cell transformation and the rate of tumor development through increased rate of genetic mutation.[,]
  3. Several infections cause intracellular accumulation of the pathogen, leading to suppression of apoptosis primarily through modulation of the expression of Bcl-2 family proteins or by inactivation of retinoblastoma protein, pRb.[,] This strategy provides a niche in which the intracellular pathogen can survive in spite of the attempts of the host immune system to destroy the infected cells by apoptosis. Thus, it allows the partially transformed cells to evade the self-destructive process and progress to a higher level of transformation, ultimately becoming tumorogenic.
  4. Many pathogenic bacteria causing chronic infection with intracellular access subvert host cell signaling pathways, enhancing the survival of pathogen.[] The regulation of these signaling factors is central to the development or inhibition of tumor formation. Such infections can mimic some of the gross effects seen in tumorogenesis, and indeed the precancerous lesion formed in such infections can regress with antibiotic treatment and clearance of bacteria.
  5. Another possible mechanism is the metabolism of potentially carcinogenic substances by the bacteria. This is of relevance in the oral cavity, where the pre-existing local microflora may facilitate tumourogenesis by converting ethanol into its carcinogenic derivative, acetaldehyde to levels capable of inducing DNA damage, mutagenesis and secondary hyperproliferation of the epithelium.[,] Also, this is evidential from the increased levels of microbial acetaldehyde production in heavy drinkers and smokers, supporting this concept.
  6. Microbial carcinogenesis may also involve nitrosation in which microbial cells catalyze the formation of N-nitroso compounds from the precursor’s nitrite and amines, amides or other nitrosatable compounds. Several species of bacteria encompass strains capable of catalyzing nitrosation, in particular, Escherichia coli.[] Also, yeasts and fungi may include nitrosating organisms. This particular nitrosamine appears to be a relevant candidate for the cause of carcinoma, not only of the esophagus but also of other mucosal areas such as the oral cavity.[]

Bacteria and oral cancers

For establishing the role of bacteria in the development of oral cancers, it is essential to identify the organisms that prevail in these tumor specimens. This apparent alteration of the oral microbiota in cases of oral squamous cell carcinoma is of particular interest.

This has been highlighted by a study of intraoral carcinomas that demonstrated the difference in the microflora of the tumor tissue with the control sites [Table 2].[] Although the great diversity of species isolated from a relatively low number of patients’ specimen made it difficult to draw the statistical analysis, a number of interesting trends were apparent.

Table 2

<!--caption a7-->

Various microorganisms associated with oral cancers

Bacteria isolated from the tumorous specimen Exiguobacterium oxidotolerans, Prevotella melaninogenica, Staphylococcus aureus and Veillonella parvula
Bacteria isolated with the tumor associated saliva sample Capnocytophaga gingivalis, Prevotella melaninogenica, Streptococcus mitis

Figure 2:Bacteria laden with “Smart polystyrene nanoparticles” which can carry genes, drugs, nanosensors or other cargo into the interior of host cells for early diagnosis and treatment of oral cancers

CONCLUSIONS

To summarize, recent research has enlightened us with wider range of information regarding the bacterial mechanisms used to cause, colonize or cure cancer. However, yet many doubts remain untouched. These are: Is it the microbial infections that initiate cancer, or is it the pre-existing cancer that lowers the host’s immunity facilitating secondary microbial colonization? Can the highly site-specific colonization of certain bacteria be of any value in its diagnosis or treatment? Could attenuated bacteria be used in vaccines to modulate host’s immunity against cancer? This calls for further exploration on this subject, which would clear our understanding of the role of the microbial detection, not only in prevention or early diagnosis of oral cancers but also in providing an effective treatment and improving the survival.

Footnotes

Source of Support: Nil

Conflict of Interest: None declared.

References

  1. Sugerman PB, Joseph BK, SavageNW. The role of oncogenes, tumour suppressor genes and growth factors in oral squamous cell carcinoma: A case of apoptosis versus proliferation. Oral Dis 1995;1:172-88.
  2. Rodrigues VC, MossSM, Tuomainen H. Oral cancer in the UK: To screen or not to screen. Oral Oncol 1998;34:454-65.
  3. World Health Organization. World Health Report. Geneva: World Health Organization; 1996.
  4. Johnson N. Tobacco use and oral cancer: A global perspective. J Dent Educ 2001;65:328-39.
  5. Scully C. Oral squamous cell carcinoma; from an hypothesis about a virus, to concern about possible sexual transmission. Oral Oncol 2002;38:227-34.
  6. Cawson RA. Leukoplakia and oral cancer. Proc R Soc Med 1969;62:610-4.
  7. Lissowska J, Pilarska A, Pilarski P, Samolczyk-Wanyura D, Piekarczyk J, Bardin-Mikollajczak A, et al. Smoking, alcohol, diet, dentition and sexual practices in the epidemiology of oral cancer in Poland. Eur J Cancer Prev 2003;12:25-33.
  8. Tran N, Rose B, O′Brien CJ. Role of HPV in the etiology of Head and Neck Cancer. Head Neck Oncol 2007;29:64-70.
  9. D′Costa J, Saranath D, Dedhia P, Sanghvi V, Mehta AR. Detection of HPV-16 genome in human oral cancers and potentially malignant lesions from India. Oral Oncol 1998;34:413-20.
  10. Nagy KN, Sondoki I, Nagy SE, Newman HN. The microflora associated with human oral carcinomas. Oral Oncol 1998;34:304-8.
  11. Hooper SJ, Crean SJ, Fardy MJ, Lewis MA, Spratt DA, Wade WG, et al. A molecular analysis of the bacteria present within oral squamous cell carcinoma. J Med Microbiol 2007;56:1651-9.
  12. Ord RA, Blanchaert RH Jr. Current management of oral cancer. A multidisciplinary approach. J Am Dent Assoc 2001;132:19S-23.
  13. Crowe SE. Helicobacter infection, chronic inflammation, and the development of malignancy. Curr Opin Gastroenterol 2005;1:32-8.
  14. Montalban C, Santon A, Boixeda D, Bellas C. Regression of gastric high grade mucosa associated lymphoid tissue (MALT) lymphoma after Helicobacter pylori eradication. Gut 2001;49:584-7.
  15. Persing DH, Prendergast FG. Infection, immunity, and cancer. Arch Pathol Lab Med 1999;123:1015-22.
  16. Vaishnavi C, Kochhar R, Singh G, Kumar S, Singh S, Singh K. Epidemiology of typhoid carriers among blood donors and patients with biliary, gastrointestinal and other related diseases. Microbiol Immunol 2005;49:107-12.
  17. ;Lax AJ, Thomas W. How bacteria could cause cancer: One step at a time. Trends Microbiol 2002;10:293-9.
  18. Dutta U, Garg PK, Kumar R, Tandon RK. Typhoid carriers among patients with gallstones are at increased risk for carcinoma of the gallbladder. Am J Gastroenterol 2000;95:784-7.
  19. Shukla VK, Singh H, Pandey M, Upadhyay SK, Nath G. Carcinoma of the gallbladder - is it a sequel of typhoid? Dig Dis Sci 2000;45:900-3.
  20. Littman AJ, White E, Jackson LA, Thornquist MD, Gaydos CA, Goodman GE, et al. Chlamydia pneumoniae infection and risk of lung cancer. Cancer Epidemiol Biomarkers Prev 2004;13:1624-30.
  21. Koyi H, Branden E, Gnarpe J, Gnarpe H, Steen B. An association between chronic infection with Chlamydia pneumoniae and lung cancer. A prospective 2-year study. APMIS 2001;109:572-80.
  22. Anttila T, Koskela P, Leinonen M, Laukkanen P, Hakulinen T, Lehtinen M, et al. Chlamydia pneumoniae infection and the risk of female early-onset lung cancer. Int J Cancer 2003;107:681-2.
  23. Biarc J, Nguyen IS, Pini A, Gosse F, Richert S, Thierse D, et al. Carcinogenic properties of proteins with pro-inflammatory activity from Streptococcus infantarius (formerly S. bovis). Carcinogenesis 2004;25:1477-84.
  24. Gold JS, Bayar S, Salem RR. Association of Streptococcus bovis bacteremia with colonic neoplasia and extracolonic malignancy. neoplasia and extracolonic malignancy. Arch Surg 2004;139:760-5.
  25. Ellmerich S, Scholler M, Duranton B, Gosse F, Galluser M, Klein JP, et al. Promotion of intestinal carcinogenesis by Streptococcus bovis. Carcinogenesis 2000;21:753-6.
  26. Zarkin BA, Lillemoe KD, Cameron JL, Effron PN, Magnuson TH, Pitt HA. The triad of Streptococcus bovis bacteremia, colonic pathology, and liver disease. Ann Surg 1990;211:786-91.
  27. Kocazeybek B. Chronic Chlamydophila pneumoniae infection in lung cancer, a risk factor: A case-control study. J Med Microbiol 2003;52:721-6.
  28. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
  29. Parsonnet J. Bacterial infection as a cause of cancer. Environ Health Perspect 1995;103:263-8.
  30. Nougayrede JP, Taieb F, De Rycke J, Oswald E. Cyclomodulins: Bacterial effectors that modulate the eukaryotic cell cycle. Trends Microbiol 2005;13:103-10.
  31. Lara-Tejero M, Galán JE. A bacterial toxin that controls cell cycle progression as a deoxyribonuclease I-like protein. Science 2000;290:354-7.
  32. Lax AJ. Bacterial toxins and cancer - case to answer? Nat Rev Microbiol 2005;3:343-9.
  33. Pöschl G, Seitz HK. Alcohol and cancer. Alcohol Alcohol 2004;39:155-65.
  34. Salaspuro MP. Acetaldehyde, microbes, and cancer of the digestive tract. Crit Rev Clin Lab Sci 2003;40:183-208.
  35. Calmels S, Ohshima H, Vincent P, Gounot AM, Bartsch H. Screening of microorganisms for nitrosation catalysis at pH 7 and kinetic studies on nitrosamine formation from-secondary amines by E. coli strains. Carcinogenesis 1985;6:911-5.
  36. Lijinsky W, Saavedra JE, Reuber MD, Singer SS. Esophageal carcinogenesis in F344 rats by nitrosomethylethylamines substituted in the ethyl group. J Natl Cancer Inst 1982;68:681-4.
  37. Takahashi N. Acid-neutralizing activity during amino acid fermentation by Porphyromonas gingivalis, Prevotella intermedia and Fusobacterium nucleatum. Oral Microbiol Immunol 2003;18:109-13.
  38. Raghunand N, Gatenby RA, Gillies RJ. Microenvironmental and cellular consequences of altered blood flow in tumours. Br J Radiol 2003;76:S11-22.
  39. Sasaki H, Ishizuka T, Muto M, Nezu M, Nakanishi Y, Inagaki Y, et al. Presence of Streptococcus anginosus DNA in esophageal cancer, dysplasia of esophagus, and gastric cancer. Cancer Res 1998;58:2991-5.
  40. Shiga K, Tadeda M, Saijo S, Hori T, Sato I, Tateno H, et al. Presence of Streptococcus infection in extra-oropharyngeal head and neck squamous cell carcinoma and its implication in carcinogenesis. Oncol Rep 2001;8:245-8.
  41. Morita E, Narikiyo M, Yano A, Nishimura E, Igaki H, Sasaki H, et al. Different frequencies of Streptococcus anginosus infection in oral cancer and esophageal cancer. Cancer Sci 2003;94:492-6.
  42. Mager DL, Haffajee AD, Devlin PM, Norris CM, Posner MR, Goodson JM. The salivary microbiota as a diagnostic indicator of oral cancer: A descriptive, non-randomized study of cancer-free and oral squamous cell carcinoma subjects.J Transl Med 2005;3:27.
  43. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
  44. Cover TL, Krishna US, Israel DA, Peek RM Jr. Induction of gastric epithelial cell apoptosis by Helicobacter pylori vacuolating cytotoxin. Cancer Res 2003;63:951-7.
  45. Correa P, Miller MJ. Carcinogenesis, apoptosis and cell proliferation. Br Med Bull 1998;54:151-62.
  46. Mergenhagen SE, Sandberg AL, Chassy BM, Brennan MJ, Yeung MK, Donkersloot JA, et al. Molecular basis of bacterial adhesion in the oral cavity. Rev Infect Dis 1987;9:S467-74.
  47. Sojar HT, Sharma A, Genco RJ. Porphyromonas gingivalis fimbriae bind to cytokeratin of epithelial cells. Infect Immun 2002;70:96-101.
  48. Khlgatian M, Nassar H, Chou HH, Gibson FC 3 rd , Genco CA. Fimbria-dependent activation of cell adhesion molecule expression in Porphyromonas gingivalis-infected endothelial cells. Infect Immun 2002;70:257-67.
  49. Bhavanandan VP. Cancer-associated mucins and mucin-type glycoproteins. Glycobiology 1991;1:493-503.
  50. Neeser JR, Grafstrom RC, Woltz A, Brassart D, Fryder V, Guggenheim B. A 23 kDa membrane glycoprotein bearing NeuNAc alpha 2-3Gal beta 1-3GalNAc O-linked carbohydrate chains acts as a receptor for Streptococcus sanguis OMZ 9 on human buccal epithelial cells. Glycobiology 1995;5:97-104.
  51. Holmes JD, Dierks EJ, Homer LD, Potter BE. Is detection of oral and oropharyngeal squamous cancer by a dental health care provider associated with a lower stage at diagnosis? J Oral Maxillofac Surg 2003;61:285-91.
  52. Richardson MA, Ramirez T, Russell NC, Moye LA. Coley toxins immunotherapy: A retrospective review. Altern Ther Health Med 1999;5:42-7.
  53. Zacharski LR, Ornstein DL, Gabazza EC, D′Alessandro-Gabazza CN, Brugarolas A, Schneider J. Treatment of malignancy by activation of the plasminogen system. Semin Thromb Hemost 2002;28:5-18.
  54. Niethammer AG, Xiang R, Ruehlmann JM, Lode HN, Dolman CS, Gillies SD et al. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma. Cancer Res 2001;61:6178-84.
  55. Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 2002;8:1369-75.
  56. Radvanyi L. Discovery and immunologic validation of new antigens for therapeutic cancer vaccines. Int Arch Allergy Immunol 2004;133:179-97.
  57. Pardoll D. Cancer vaccines. Nat Med 1998;4:525-31.
  58. Niphon N. Bacteria ferry nanoparticles into cells for early diagnosis, treatment 2007.

Figure 1:Various proposed paradigms for bacterial role in carcinogenesis

Figure 2:Bacteria laden with “Smart polystyrene nanoparticles” which can carry genes, drugs, nanosensors or other cargo into the interior of host cells for early diagnosis and treatment of oral cancers

References

  1. Sugerman PB, Joseph BK, SavageNW. The role of oncogenes, tumour suppressor genes and growth factors in oral squamous cell carcinoma: A case of apoptosis versus proliferation. Oral Dis 1995;1:172-88.
  2. Rodrigues VC, MossSM, Tuomainen H. Oral cancer in the UK: To screen or not to screen. Oral Oncol 1998;34:454-65.
  3. World Health Organization. World Health Report. Geneva: World Health Organization; 1996.
  4. Johnson N. Tobacco use and oral cancer: A global perspective. J Dent Educ 2001;65:328-39.
  5. Scully C. Oral squamous cell carcinoma; from an hypothesis about a virus, to concern about possible sexual transmission. Oral Oncol 2002;38:227-34.
  6. Cawson RA. Leukoplakia and oral cancer. Proc R Soc Med 1969;62:610-4.
  7. Lissowska J, Pilarska A, Pilarski P, Samolczyk-Wanyura D, Piekarczyk J, Bardin-Mikollajczak A, et al. Smoking, alcohol, diet, dentition and sexual practices in the epidemiology of oral cancer in Poland. Eur J Cancer Prev 2003;12:25-33.
  8. Tran N, Rose B, O′Brien CJ. Role of HPV in the etiology of Head and Neck Cancer. Head Neck Oncol 2007;29:64-70.
  9. D′Costa J, Saranath D, Dedhia P, Sanghvi V, Mehta AR. Detection of HPV-16 genome in human oral cancers and potentially malignant lesions from India. Oral Oncol 1998;34:413-20.
  10. Nagy KN, Sondoki I, Nagy SE, Newman HN. The microflora associated with human oral carcinomas. Oral Oncol 1998;34:304-8.
  11. Hooper SJ, Crean SJ, Fardy MJ, Lewis MA, Spratt DA, Wade WG, et al. A molecular analysis of the bacteria present within oral squamous cell carcinoma. J Med Microbiol 2007;56:1651-9.
  12. Ord RA, Blanchaert RH Jr. Current management of oral cancer. A multidisciplinary approach. J Am Dent Assoc 2001;132:19S-23.
  13. Crowe SE. Helicobacter infection, chronic inflammation, and the development of malignancy. Curr Opin Gastroenterol 2005;1:32-8.
  14. Montalban C, Santon A, Boixeda D, Bellas C. Regression of gastric high grade mucosa associated lymphoid tissue (MALT) lymphoma after Helicobacter pylori eradication. Gut 2001;49:584-7.
  15. Persing DH, Prendergast FG. Infection, immunity, and cancer. Arch Pathol Lab Med 1999;123:1015-22.
  16. Vaishnavi C, Kochhar R, Singh G, Kumar S, Singh S, Singh K. Epidemiology of typhoid carriers among blood donors and patients with biliary, gastrointestinal and other related diseases. Microbiol Immunol 2005;49:107-12.
  17. ;Lax AJ, Thomas W. How bacteria could cause cancer: One step at a time. Trends Microbiol 2002;10:293-9.
  18. Dutta U, Garg PK, Kumar R, Tandon RK. Typhoid carriers among patients with gallstones are at increased risk for carcinoma of the gallbladder. Am J Gastroenterol 2000;95:784-7.
  19. Shukla VK, Singh H, Pandey M, Upadhyay SK, Nath G. Carcinoma of the gallbladder - is it a sequel of typhoid? Dig Dis Sci 2000;45:900-3.
  20. Littman AJ, White E, Jackson LA, Thornquist MD, Gaydos CA, Goodman GE, et al. Chlamydia pneumoniae infection and risk of lung cancer. Cancer Epidemiol Biomarkers Prev 2004;13:1624-30.
  21. Koyi H, Branden E, Gnarpe J, Gnarpe H, Steen B. An association between chronic infection with Chlamydia pneumoniae and lung cancer. A prospective 2-year study. APMIS 2001;109:572-80.
  22. Anttila T, Koskela P, Leinonen M, Laukkanen P, Hakulinen T, Lehtinen M, et al. Chlamydia pneumoniae infection and the risk of female early-onset lung cancer. Int J Cancer 2003;107:681-2.
  23. Biarc J, Nguyen IS, Pini A, Gosse F, Richert S, Thierse D, et al. Carcinogenic properties of proteins with pro-inflammatory activity from Streptococcus infantarius (formerly S. bovis). Carcinogenesis 2004;25:1477-84.
  24. Gold JS, Bayar S, Salem RR. Association of Streptococcus bovis bacteremia with colonic neoplasia and extracolonic malignancy. neoplasia and extracolonic malignancy. Arch Surg 2004;139:760-5.
  25. Ellmerich S, Scholler M, Duranton B, Gosse F, Galluser M, Klein JP, et al. Promotion of intestinal carcinogenesis by Streptococcus bovis. Carcinogenesis 2000;21:753-6.
  26. Zarkin BA, Lillemoe KD, Cameron JL, Effron PN, Magnuson TH, Pitt HA. The triad of Streptococcus bovis bacteremia, colonic pathology, and liver disease. Ann Surg 1990;211:786-91.
  27. Kocazeybek B. Chronic Chlamydophila pneumoniae infection in lung cancer, a risk factor: A case-control study. J Med Microbiol 2003;52:721-6.
  28. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
  29. Parsonnet J. Bacterial infection as a cause of cancer. Environ Health Perspect 1995;103:263-8.
  30. Nougayrede JP, Taieb F, De Rycke J, Oswald E. Cyclomodulins: Bacterial effectors that modulate the eukaryotic cell cycle. Trends Microbiol 2005;13:103-10.
  31. Lara-Tejero M, Galán JE. A bacterial toxin that controls cell cycle progression as a deoxyribonuclease I-like protein. Science 2000;290:354-7.
  32. Lax AJ. Bacterial toxins and cancer - case to answer? Nat Rev Microbiol 2005;3:343-9.
  33. Pöschl G, Seitz HK. Alcohol and cancer. Alcohol Alcohol 2004;39:155-65.
  34. Salaspuro MP. Acetaldehyde, microbes, and cancer of the digestive tract. Crit Rev Clin Lab Sci 2003;40:183-208.
  35. Calmels S, Ohshima H, Vincent P, Gounot AM, Bartsch H. Screening of microorganisms for nitrosation catalysis at pH 7 and kinetic studies on nitrosamine formation from-secondary amines by E. coli strains. Carcinogenesis 1985;6:911-5.
  36. Lijinsky W, Saavedra JE, Reuber MD, Singer SS. Esophageal carcinogenesis in F344 rats by nitrosomethylethylamines substituted in the ethyl group. J Natl Cancer Inst 1982;68:681-4.
  37. Takahashi N. Acid-neutralizing activity during amino acid fermentation by Porphyromonas gingivalis, Prevotella intermedia and Fusobacterium nucleatum. Oral Microbiol Immunol 2003;18:109-13.
  38. Raghunand N, Gatenby RA, Gillies RJ. Microenvironmental and cellular consequences of altered blood flow in tumours. Br J Radiol 2003;76:S11-22.
  39. Sasaki H, Ishizuka T, Muto M, Nezu M, Nakanishi Y, Inagaki Y, et al. Presence of Streptococcus anginosus DNA in esophageal cancer, dysplasia of esophagus, and gastric cancer. Cancer Res 1998;58:2991-5.
  40. Shiga K, Tadeda M, Saijo S, Hori T, Sato I, Tateno H, et al. Presence of Streptococcus infection in extra-oropharyngeal head and neck squamous cell carcinoma and its implication in carcinogenesis. Oncol Rep 2001;8:245-8.
  41. Morita E, Narikiyo M, Yano A, Nishimura E, Igaki H, Sasaki H, et al. Different frequencies of Streptococcus anginosus infection in oral cancer and esophageal cancer. Cancer Sci 2003;94:492-6.
  42. Mager DL, Haffajee AD, Devlin PM, Norris CM, Posner MR, Goodson JM. The salivary microbiota as a diagnostic indicator of oral cancer: A descriptive, non-randomized study of cancer-free and oral squamous cell carcinoma subjects.J Transl Med 2005;3:27.
  43. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
  44. Cover TL, Krishna US, Israel DA, Peek RM Jr. Induction of gastric epithelial cell apoptosis by Helicobacter pylori vacuolating cytotoxin. Cancer Res 2003;63:951-7.
  45. Correa P, Miller MJ. Carcinogenesis, apoptosis and cell proliferation. Br Med Bull 1998;54:151-62.
  46. Mergenhagen SE, Sandberg AL, Chassy BM, Brennan MJ, Yeung MK, Donkersloot JA, et al. Molecular basis of bacterial adhesion in the oral cavity. Rev Infect Dis 1987;9:S467-74.
  47. Sojar HT, Sharma A, Genco RJ. Porphyromonas gingivalis fimbriae bind to cytokeratin of epithelial cells. Infect Immun 2002;70:96-101.
  48. Khlgatian M, Nassar H, Chou HH, Gibson FC 3 rd , Genco CA. Fimbria-dependent activation of cell adhesion molecule expression in Porphyromonas gingivalis-infected endothelial cells. Infect Immun 2002;70:257-67.
  49. Bhavanandan VP. Cancer-associated mucins and mucin-type glycoproteins. Glycobiology 1991;1:493-503.
  50. Neeser JR, Grafstrom RC, Woltz A, Brassart D, Fryder V, Guggenheim B. A 23 kDa membrane glycoprotein bearing NeuNAc alpha 2-3Gal beta 1-3GalNAc O-linked carbohydrate chains acts as a receptor for Streptococcus sanguis OMZ 9 on human buccal epithelial cells. Glycobiology 1995;5:97-104.
  51. Holmes JD, Dierks EJ, Homer LD, Potter BE. Is detection of oral and oropharyngeal squamous cancer by a dental health care provider associated with a lower stage at diagnosis? J Oral Maxillofac Surg 2003;61:285-91.
  52. Richardson MA, Ramirez T, Russell NC, Moye LA. Coley toxins immunotherapy: A retrospective review. Altern Ther Health Med 1999;5:42-7.
  53. Zacharski LR, Ornstein DL, Gabazza EC, D′Alessandro-Gabazza CN, Brugarolas A, Schneider J. Treatment of malignancy by activation of the plasminogen system. Semin Thromb Hemost 2002;28:5-18.
  54. Niethammer AG, Xiang R, Ruehlmann JM, Lode HN, Dolman CS, Gillies SD et al. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma. Cancer Res 2001;61:6178-84.
  55. Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 2002;8:1369-75.
  56. Radvanyi L. Discovery and immunologic validation of new antigens for therapeutic cancer vaccines. Int Arch Allergy Immunol 2004;133:179-97.
  57. Pardoll D. Cancer vaccines. Nat Med 1998;4:525-31.
  58. Niphon N. Bacteria ferry nanoparticles into cells for early diagnosis, treatment 2007.